Wird geladen...
Acyclic cucurbit[n]uril-type molecular container enables systemic delivery of effective doses of albendazole for treatment of SK-OV-3 xenograft tumors
Approximately, 40–70% of active pharmaceutical ingredients (API) are severely limited by their extremely poor aqueous solubility and consequently there is a high demand for excipients that can be used to formulate clinically relevant doses of these drug candidates. Here, proof-of-concept studies dem...
Gespeichert in:
| Veröffentlicht in: | Mol Pharm |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4783263/ https://ncbi.nlm.nih.gov/pubmed/26756920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.5b00723 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|